[
  {"doc_id":"F2020-AR-C014","type":"Annual Report","date":"2021-03-01","title":"2020 Annual Report","body":"MicroFluidics Diagnostics reported revenue of $19.5 million in 2020 with successful FlowDx platform demonstrations generating significant healthcare provider interest. Patent portfolio expanded with microfluidics processing technology protection. Key challenges include FDA regulatory pathways and manufacturing scale-up. ESG initiatives focus on healthcare access equity and sustainable manufacturing practices."},
  {"doc_id":"F2021-AR-C014","type":"Annual Report","date":"2022-02-28","title":"2021 Annual Report","body":"Revenue grew to $29.4 million with FDA 510k clearance enabling commercial market entry. International expansion commenced with European operations establishment. ISO 13485 certification achieved enhancing regulatory compliance. Technology partnerships with materials suppliers strengthen product capabilities."},
  {"doc_id":"F2022-AR-C014","type":"Annual Report","date":"2023-02-27","title":"2022 Annual Report","body":"Strong revenue growth to $45.5 million driven by Quest Diagnostics contract and DiagStream software launch. Series A funding of $25 million supports development scaling and manufacturing expansion. Global health partnerships expand market reach in emerging economies."},
  {"doc_id":"F2023-AR-C014","type":"Annual Report","date":"2024-02-29","title":"2023 Annual Report","body":"Revenue reached $59.2 million with WHO partnership expanding global health impact. Clinical success stories demonstrate improved patient outcomes and healthcare efficiency. Award recognition validates technology leadership and innovation approach."},
  {"doc_id":"F2024-AR-C014","type":"Annual Report","date":"2025-02-28","title":"2024 Annual Report","body":"Revenue of $70.8 million achieved despite temporary manufacturing challenges. Quality control enhancements restore operational excellence. FlowDx 2.0 platform launch maintains competitive positioning. APAC expansion creates regional growth opportunities."},
  {"doc_id":"DEMO-2020-04-C014","type":"Product Demonstration","date":"2020-04-30","title":"FlowDx Platform Healthcare Provider Demonstrations","body":"Comprehensive demonstrations of FlowDx point-of-care diagnostic platform to major healthcare systems including Mayo Clinic Kaiser Permanente and Cleveland Clinic. Technology showed 15-minute test results with laboratory-equivalent accuracy generating $3.2 million in pilot commitments."},
  {"doc_id":"FDA-2021-09-C014","type":"FDA Clearance","date":"2021-09-22","title":"ChipLab Microfluidic Cartridges FDA 510k Clearance","body":"FDA 510k clearance granted for ChipLab microfluidic diagnostic cartridges enabling commercial distribution in US healthcare market. Clearance covers multiple test parameters including cardiac markers inflammatory indicators and infectious disease detection."},
  {"doc_id":"QUEST-2022-12-C014","type":"Commercial Contract","date":"2022-12-15","title":"Quest Diagnostics Point-of-Care Testing Contract","body":"$18 million three-year contract with Quest Diagnostics for point-of-care testing deployment across national laboratory network. Contract includes FlowDx platform installation ChipLab cartridge supply and DiagStream analytics software licensing."},
  {"doc_id":"WHO-2023-08-C014","type":"Partnership Agreement","date":"2023-08-08","title":"WHO Global Health Initiative Partnership","body":"Strategic partnership with World Health Organization Global Health Initiative for diagnostic technology deployment in resource-limited settings. Partnership includes technology transfer training programs and subsidized pricing for qualifying healthcare providers."},
  {"doc_id":"QUALITY-2024-03-C014","type":"Quality Issue Report","date":"2024-03-12","title":"Manufacturing Quality Control Investigation","body":"Production halt initiated following detection of potential contamination in ChipLab cartridge manufacturing facility. Company implementing comprehensive quality control review and enhanced manufacturing protocols. Customer notification and voluntary recall procedures initiated."},
  {"doc_id":"RESOLVE-2024-09-C014","type":"Resolution Document","date":"2024-09-25","title":"Quality Control Enhancement Implementation","body":"Manufacturing operations resumed following successful implementation of enhanced quality control protocols. New measures include additional testing procedures improved facility controls and expanded quality assurance team. Customer confidence restoration achieved through transparent communication."},
  {"doc_id":"JV-2025-02-C014","type":"Joint Venture Agreement","date":"2025-02-10","title":"MedTech Innovation Alliance Formation","body":"Joint venture formation with Medisafe Health and NeuraGen AI creating integrated diagnostic and healthcare delivery platform. Alliance combines point-of-care testing healthcare services and AI analytics for comprehensive patient care solutions."},
  {"doc_id":"ER-2025-08-C014","type":"Earnings Release","date":"2025-08-19","title":"Q2 2025 Strong Financial Performance","body":"Record Q2 2025 revenue of $20.2 million driven by international expansion and new product launches. Full-year guidance raised based on strong pipeline and partnership momentum. Joint venture initiatives accelerate market opportunities and technology development."},
  {"doc_id":"PAT-2020-11-C014","type":"Patent Grant","date":"2020-11-18","title":"Microfluidics Sample Processing Patent","body":"Patent US11,123,456 granted for automated microfluidic sample processing technology including fluid handling sample preparation and integrated analysis capabilities. Patent provides competitive protection for core platform technology."},
  {"doc_id":"FUND-2022-05-C014","type":"Funding Document","date":"2022-05-25","title":"Series A Funding Round $25 Million","body":"Series A funding completed raising $25 million from medical technology focused venture capital firms. Funding supports manufacturing scaling product development and international market expansion. Lead investors include specialized healthcare technology funds."},
  {"doc_id":"DIAG-2022-09-C014","type":"Product Launch","date":"2022-09-12","title":"DiagStream Analytics Software Launch","body":"Commercial launch of DiagStream AI-powered diagnostic result interpretation and analytics platform. Software provides real-time result analysis trend monitoring and clinical decision support integrated with FlowDx hardware platform."},
  {"doc_id":"FLOW-2024-06-C014","type":"Product Launch","date":"2024-06-10","title":"FlowDx 2.0 Platform Launch","body":"Next-generation FlowDx 2.0 point-of-care diagnostic platform launched with enhanced testing capabilities improved user interface and expanded test menu. Platform maintains compact form factor while doubling testing throughput and accuracy."},
  {"doc_id":"ASSAY-2025-06-C014","type":"Technology Breakthrough","date":"2025-06-22","title":"Multi-Parameter Single Cartridge Assay Development","body":"Breakthrough development of multi-parameter testing capability on single ChipLab cartridge enabling simultaneous analysis of cardiac markers inflammatory indicators and metabolic panels. Technology provides comprehensive diagnostic panel in single 15-minute test."},
  {"doc_id":"EUR-2025-07-C014","type":"Regulatory Approval","date":"2025-07-15","title":"European MDR Approval Achievement","body":"EU Medical Device Regulation approval achieved enabling commercial distribution across European markets. Approval covers FlowDx platform ChipLab cartridges and DiagStream software meeting comprehensive European regulatory requirements."},
  {"doc_id":"LEAD-2025-08-C014","type":"Market Recognition","date":"2025-08-10","title":"Point-of-Care Diagnostics Market Leadership Recognition","body":"Industry analyst recognition as leading innovator in point-of-care diagnostic technology. Recognition based on technology advancement market penetration and clinical outcome improvements demonstrated across healthcare provider network."}
]
